|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: Promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Puglisi MA, Tesori V, Lattanzi W,
Gasbarrini GB and Gasbarrini A: Colon cancer stem cells:
Controversies and perspectives. World J Gastroenterol.
19:2997–3006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fanali C, Lucchetti D, Farina M, Corbi M,
Cufino V, Cittadini A and Sgambato A: Cancer stem cells in
colorectal cancer from pathogenesis to therapy: Controversies and
perspectives. World J Gastroenterol. 20:923–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ropponen KM, Eskelinen MJ, Lipponen PK,
Alhava E and Kosma VM: Expression of CD44 and variant proteins in
human colorectal cancer and its relevance for prognosis. Scand J
Gastroenterol. 33:301–309. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fernández JC, Vizoso FJ, Corte MD, Gava
RR, Corte MG, Suárez JP, García-Muñíz JL and García-Morán M: CD44s
expression in resectable colorectal carcinomas and surrounding
mucosa. Cancer Invest. 22:878–885. 2004. View Article : Google Scholar
|
|
9
|
Huh JW, Kim HR, Kim YJ, Lee JH, Park YS,
Cho SH and Joo JK: Expression of standard CD44 in human colorectal
carcinoma: Association with prognosis. Pathol Int. 59:241–246.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harada N, Mizoi T, Kinouchi M, Hoshi K,
Ishii S, Shiiba K, Sasaki I and Matsuno S: Introduction of
antisense CD44S CDNA down-regulates expression of overall CD44
isoforms and inhibits tumor growth and metastasis in highly
metastatic colon carcinoma cells. Int J Cancer. 91:67–75. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du L, Wang H, He L, Zhang J, Ni B, Wang X,
Jin H, Cahuzac N, Mehrpour M, Lu Y, et al: CD44 is of functional
importance for colorectal cancer stem cells. Clin Cancer Res.
14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park YS, Huh JW, Lee JH and Kim HR: shRNA
against CD44 inhibits cell proliferation, invasion and migration,
and promotes apoptosis of colon carcinoma cells. Oncol Rep.
27:339–346. 2012.
|
|
14
|
Cho SH, Park YS, Kim HJ, Kim CH, Lim SW,
Huh JW, Lee JH and Kim HR: CD44 enhances the epithelial-mesenchymal
transition in association with colon cancer invasion. Int J Oncol.
41:211–218. 2012.PubMed/NCBI
|
|
15
|
Short JJ and Curiel DT: Oncolytic
adenoviruses targeted to cancer stem cells. Mol Cancer Ther.
8:2096–2102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
St George JA: Gene therapy progress and
prospects: Adenoviral vectors. Gene Ther. 10:1135–1141. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McDougal JS, Cort SP, Kennedy MS,
Cabridilla CD, Feorino PM, Francis DP, Hicks D, Kalyanaraman VS and
Martin LS: Immunoassay for the detection and quantitation of
infectious human retrovirus, lymphadenopathy-associated virus
(LAV). J Immunol Methods. 76:171–183. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang GJ, Kaiser AM, Mills S, Rafferty JF
and Buie WD; Standards Practice Task Force of the American Society
of Colon and Rectal Surgeons: Practice parameters for the
management of colon cancer. Dis Colon Rectum. 55:831–843. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH and
Kim HR: Colon cancer stem cell markers CD44 and CD133 in patients
with colorectal cancer and synchronous hepatic metastases. Int J
Oncol. 46:1582–1588. 2015.PubMed/NCBI
|
|
20
|
Bendardaf R, Algars A, Elzagheid A,
Korkeila E, Ristamäki R, Lamlum H, Collan Y, Syrjänen K and
Pyrhönen S: Comparison of CD44 expression in primary tumours and
metastases of colorectal cancer. Oncol Rep. 16:741–746.
2006.PubMed/NCBI
|
|
21
|
Cerullo V, Koski A, Vähä-Koskela M and
Hemminki A: Chapter eight - Oncolytic adenoviruses for cancer
immunotherapy: Data from mice, hamsters, and humans. Adv Cancer
Res. 115:265–318. 2012. View Article : Google Scholar
|
|
22
|
Bourke MG, Salwa S, Harrington KJ,
Kucharczyk MJ, Forde PF, de Kruijf M, Soden D, Tangney M, Collins
JK and O'Sullivan GC: The emerging role of viruses in the treatment
of solid tumours. Cancer Treat Rev. 37:618–632. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hawkins LK, Lemoine NR and Kirn D:
Oncolytic biotherapy: A novel therapeutic plafform. Lancet Oncol.
3:17–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like Forkhead transcription factors mediate cell-cycle
regulation by Ras and PKB through p27kip1. Nature.
404:782–787. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao X, Gan L, Pan H, Kan D, Majeski M,
Adam SA and Unterman TG: Multiple elements regulate
nuclear/cytoplasmic shuttling of FOXO1: Characterization of
phosphorylation- and 14-3-3-dependent and -independent mechanisms.
Biochem J. 378:839–849. 2004. View Article : Google Scholar
|
|
28
|
Downward J: PI 3-kinase, Akt and cell
survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar
|
|
30
|
Zheng JH, Viacava Follis A, Kriwacki RW
and Moldoveanu T: Discoveries and controversies in BCL-2
protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar
|
|
31
|
Um HD: Bcl-2 family proteins as regulators
of cancer cell invasion and metastasis: A review focusing on
mitochondrial respiration and reactive oxygen species. Oncotarget.
7:5193–5203. 2016.
|
|
32
|
Galluzzi L, López-Soto A, Kumar S and
Kroemer G: Caspases connect cell-death signaling to organismal
homeostasis. Immunity. 44:221–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Man SM and Kanneganti TD: Converging roles
of caspases in inflammasome activation, cell death and innate
immunity. Nat Rev Immunol. 16:7–21. 2016. View Article : Google Scholar :
|
|
34
|
Horibata S, Vo TV, Subramanian V, Thompson
PR and Coonrod SA: Utilization of the soft agar colony formation
assay to identify inhibitors of tumorigenicity in breast cancer
cells. J Vis Exp. e527272015.PubMed/NCBI
|
|
35
|
Nemunaitis J, Cunningham C, Buchanan A,
Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson
S, et al: Intravenous infusion of a replication-selective
adenovirus (ONYX-015) in cancer patients: Safety, feasibility and
biological activity. Gene Ther. 8:746–759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reid TR, Freeman S, Post L, McCormick F
and Sze DY: Effects of Onyx-015 among metastatic colorectal cancer
patients that have failed prior treatment with 5-FU/leucovorin.
Cancer Gene Ther. 12:673–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kemeny N, Brown K, Covey A, Kim T,
Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M,
Glasschroeder B, et al: Phase I, open-label, dose-escalating study
of a genetically engineered herpes simplex virus, NV1020, in
subjects with metastatic colorectal carcinoma to the liver. Hum
Gene Ther. 17:1214–1224. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fong Y, Kim T, Bhargava A, Schwartz L,
Brown K, Brody L, Covey A, Karrasch M, Getrajdman G, Mescheder A,
et al: A herpes oncolytic virus can be delivered via the
vasculature to produce biologic changes in human colorectal cancer.
Mol Ther. 17:389–394. 2009. View Article : Google Scholar
|
